Long Ideas - Palatin Technologies (AMEX:PTN) announced this morning that its Phase IIb trial for bremelanotide met its primary endpoint, as well as secondary endpoints, for the treatment … Continue Reading
Read NowQuick Picks - Acadia Pharmaceuticals (NASDAQ:ACAD) announced its 3Q financial results Monday, reiterating the expectation for top-line pimavanserin data by the end of the month and reporting the … Continue Reading
Read NowQuick Picks - Amedisys, Inc. (NASDAQ:AMED) reported 3Q 2012 earnings per share (EPS) of $0.33. The results appear to be better-than-expected given the $0.27 Consensus estimate, however, excluding … Continue Reading
Read NowLong Ideas - In one of Monday’s notable volume abnormalities, shares of Pharmacyclics (NASDAQ:PCYC) have exchanged hands at more than five times average volume, and PCYC is down … Continue Reading
Read NowLong Ideas - As expected, the FDA will require Ventrus Biosciences (NASDAQ:VTUS) to complete a second Phase III study of diltiazem hydrochloride cream (VEN-307) before submitting a New … Continue Reading
Read NowQuick Picks - Chalk another “nuc” up to the FDA’s growing list of safety-related development interruptions. On Tuesday, BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that it has withdrawn an Investigational … Continue Reading
Read NowQuick Picks - Catalyst Pharmaceutical Partners (NASDAQ:CPRX) climbed as much as 18% ahead of the bell Wednesday after the company announced that it has licensed the rights to … Continue Reading
Read Now